Mow Jonathan P Insider Trades

Insider Trading History

Track insider trading activity for Mow Jonathan P. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $9.29k 132,502 shares
Last Trade
May 20, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$8.75k 10,918 shares
$0.80
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $27k 385,000 shares
Last Trade
Feb 24, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$528k 467,500 shares
$1.13
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $12.1k 172,473 shares
Last Trade
Nov 19, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$13.3k 5,623 shares
$2.36
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $11.7k 166,850 shares
Last Trade
Nov 03, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$76.4k 20,000 shares
$3.82
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $7.62k 108,767 shares
Last Trade
Nov 03, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$76.4k 20,000 shares
$3.82
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $10.3k 146,850 shares
Last Trade
Aug 27, 2021 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$66k 20,000 shares
$3.30
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $9.03k 128,767 shares
Last Trade
Aug 27, 2021 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$66k 20,000 shares
$3.30
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $8.89k 126,850 shares
Last Trade
May 20, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$13k 3,964 shares
$3.29
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $16.4k 234,000 shares
Last Trade
Feb 05, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.01M 234,000 shares
$4.31
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $8.61k 122,886 shares
Last Trade
Nov 20, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$12.9k 3,643 shares
$3.53
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $10.4k 148,767 shares
Last Trade
Aug 21, 2020 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$37.9k 10,000 shares
$3.79
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $8.36k 119,243 shares
Last Trade
Aug 21, 2020 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$37.9k 10,000 shares
$3.79
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $20.3k 290,000 shares
Last Trade
Feb 12, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.51M 290,000 shares
$5.19
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $7.66k 109,243 shares
Last Trade
Sep 06, 2019 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$96k 19,000 shares
$5.05
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $11.1k 158,767 shares
Last Trade
Sep 06, 2019 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$96k 19,000 shares
$5.05
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $0 0 shares
Last Trade
May 20, 2019 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$203k 19,131 shares
$10.62
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $6.33k 90,243 shares
Last Trade
May 20, 2019 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$203k 19,131 shares
$10.62
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $4.98k 71,112 shares
Last Trade
May 17, 2019 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$214k 19,913 shares
$10.75
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $0 0 shares
Last Trade
May 17, 2019 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$214k 19,913 shares
$10.75
$0.07
PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals PHAS
Chief Executive Officer
Holding Value $18.4k 263,000 shares
Last Trade
Feb 27, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$828k 263,000 shares
$3.15
$0.07

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up